Details of the Drug

General Information of Drug (ID: DM8SXYG)

Drug Name
Lamotrigine
Synonyms
Crisomet; Labileno; Lamictal; Lamictin; Lamiktal; Lamitor; Lamotrigina; Lamotriginum; Desitin Brand of Lamotrigine; Faes Brand of Lamotrigine; Glaxo Wellcome Brand of Lamotrigine; GlaxoSmithKline Brand of Lamotrigine; Juste Brand of Lamotrigine; Lamictal Cd; Lamictal ODT; Lamictal XR; Lamotrigina [Spanish]; Lamotriginum [Latin]; BW 430C; GI 267119X; GW 273293; L 3791; BW-430C; EUR-1048; Lamictal (TN); Lamictin (TN); Lamotrigine [USAN:INN:BAN]; Lamotrigine (JAN/USAN/INN); 3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine; 3,5-Diamino-6-(2,3-dichlorophenyl)-as-triazine; 3,5-diamino-6-(2,3-dichlorophenyl)-as-triazine; 6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diamine; 6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diyldiamine; 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine
Indication
Disease Entry ICD 11 Status REF
Bipolar disorder 6A60 Approved [1], [2]
Epilepsy 8A60-8A68 Approved [1], [2]
Therapeutic Class
Anticonvulsants
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 256.089
Topological Polar Surface Area (xlogp) 1.4
Rotatable Bond Count (rotbonds) 1
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Bioavailability
97.6% of drug becomes completely available to its intended biological destination(s) [4]
Clearance
The clearance of drug is 0.18-1.21 mL/min/kg [5]
Elimination
Following oral administration of 240 mg radiolabelled lamotrigine, about 94% of total drug and its metabolites administered is recovered in the urine and 2% is recovered in the feces [6]
Half-life
The concentration or amount of drug in body reduced by one-half in 14 - 59 hours [7]
Metabolism
The drug is metabolized via the glucuronidated, forming 2-N-glucuronide conjugate [6]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 27.89137 micromolar/kg/day [8]
Vd
The volume of distribution (Vd) of drug is 0.9-1.3 L/kg [5]
Water Solubility
The ability of drug to dissolve in water is measured as 0.17 mg/mL [3]
Chemical Identifiers
Formula
C9H7Cl2N5
IUPAC Name
6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine
Canonical SMILES
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N
InChI
InChI=1S/C9H7Cl2N5/c10-5-3-1-2-4(6(5)11)7-8(12)14-9(13)16-15-7/h1-3H,(H4,12,13,14,16)
InChIKey
PYZRQGJRPPTADH-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3878
ChEBI ID
CHEBI:6367
CAS Number
84057-84-1
DrugBank ID
DB00555
TTD ID
D03FLC
VARIDT ID
DR00056
INTEDE ID
DR0913
ACDINA ID
D00348

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Voltage-gated sodium channel alpha Nav1.9 (SCN11A) TTN9VTF SCNBA_HUMAN Blocker [9]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [10]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [11]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [12]
UDP-glucuronosyltransferase 1A3 (UGT1A3) DEF2WXN UD13_HUMAN Substrate [13]
UDP-glucuronosyltransferase 1A4 (UGT1A4) DELOY3P UD14_HUMAN Substrate [14]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Lamotrigine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Levomilnacipran DMV26S8 Moderate Antagonize the effect of Lamotrigine when combined with Levomilnacipran. Chronic pain [MG30] [61]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Lamotrigine and Olopatadine. Conjunctiva disorder [9A60] [62]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Lamotrigine and Ethanol. Cystitis [GC00] [62]
Sertraline DM0FB1J Moderate Antagonize the effect of Lamotrigine when combined with Sertraline. Depression [6A70-6A7Z] [61]
Vilazodone DM4LECQ Moderate Antagonize the effect of Lamotrigine when combined with Vilazodone. Depression [6A70-6A7Z] [61]
Paroxetine DM5PVQE Moderate Antagonize the effect of Lamotrigine when combined with Paroxetine. Depression [6A70-6A7Z] [61]
Vortioxetine DM6F1PU Moderate Antagonize the effect of Lamotrigine when combined with Vortioxetine. Depression [6A70-6A7Z] [61]
Milnacipran DMBFE74 Moderate Antagonize the effect of Lamotrigine when combined with Milnacipran. Depression [6A70-6A7Z] [61]
Escitalopram DMFK9HG Moderate Antagonize the effect of Lamotrigine when combined with Escitalopram. Depression [6A70-6A7Z] [61]
Desvenlafaxine DMHD4PE Moderate Antagonize the effect of Lamotrigine when combined with Desvenlafaxine. Depression [6A70-6A7Z] [61]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Lamotrigine and Esketamine. Depression [6A70-6A7Z] [63]
Primidone DM0WX6I Moderate Increased metabolism of Lamotrigine caused by Primidone mediated induction of UGT. Epilepsy/seizure [8A61-8A6Z] [64]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Lamotrigine caused by Fosphenytoin mediated induction of UGT. Epilepsy/seizure [8A61-8A6Z] [64]
Phenobarbital DMXZOCG Moderate Increased metabolism of Lamotrigine caused by Phenobarbital mediated induction of UGT. Epilepsy/seizure [8A61-8A6Z] [64]
Carbamazepine DMZOLBI Moderate Increased metabolism of Lamotrigine caused by Carbamazepine mediated induction of UGT. Epilepsy/seizure [8A61-8A6Z] [64]
Rifampin DMA8J1G Moderate Increased metabolism of Lamotrigine caused by Rifampin mediated induction of UGT. HIV-infected patients with tuberculosis [1B10-1B14] [65]
Lopinavir DMITQS0 Moderate Increased metabolism of Lamotrigine caused by Lopinavir mediated induction of UGT. Human immunodeficiency virus disease [1C60-1C62] [63]
Atazanavir DMSYRBX Moderate Decreased metabolism of Lamotrigine caused by Atazanavir mediated inhibition of UGT. Human immunodeficiency virus disease [1C60-1C62] [63]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Lamotrigine and Porfimer Sodium. Lung cancer [2C25] [66]
Chloroquine DMSI5CB Moderate Antagonize the effect of Lamotrigine when combined with Chloroquine. Malaria [1F40-1F45] [63]
Hydroxychloroquine DMSIVND Moderate Antagonize the effect of Lamotrigine when combined with Hydroxychloroquine. Malaria [1F40-1F45] [63]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Lamotrigine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [67]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Lamotrigine and Lasmiditan. Migraine [8A80] [68]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Lamotrigine and Flibanserin. Mood disorder [6A60-6E23] [69]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Lamotrigine and Thalidomide. Multiple myeloma [2A83] [70]
Orlistat DMRJSP8 Moderate Altered absorption of Lamotrigine caused by Orlistat. Obesity [5B80-5B81] [71]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Lamotrigine and Apraclonidine. Optic nerve disorder [9C40] [72]
Dextropropoxyphene DM23HCX Major Additive CNS depression effects by the combination of Lamotrigine and Dextropropoxyphene. Pain [MG30-MG3Z] [73]
Buprenorphine DMPRI8G Major Additive CNS depression effects by the combination of Lamotrigine and Buprenorphine. Pain [MG30-MG3Z] [74]
Tizanidine DMR2IQ4 Moderate Additive CNS depression effects by the combination of Lamotrigine and Tizanidine. Tonus and reflex abnormality [MB47] [75]
⏷ Show the Full List of 30 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Acesulfame E00341 36573 Flavoring agent
Allura red AC dye E00338 33258 Colorant
Aspartame E00402 134601 Flavoring agent
Calcium carbonate E00198 10112 Binding agent; Buffering agent; Diluent; Opacifying agent
Caprylic acid E00017 379 Emulsifying agent; Flavoring agent; Surfactant
Diethyl phthalate E00135 6781 Plasticizing agent; Solvent
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Glyceryl monostearate E00310 24699 Emollient; Emulsifying agent; Emulsion stabilizing agent; Solubilizing agent; Surfactant; Viscosity-controlling agent
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Quinoline yellow WS E00309 24671 Colorant
Saccharin sodium dihydrate E00577 46942257 Flavoring agent
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearyl fumarate E00545 23665634 lubricant
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sucralose E00370 71485 Flavoring agent
Sunset yellow FCF E00255 17730 Colorant
Tricaprin E00366 69310 Emollient
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium E00625 Not Available Disintegrant
Crospovidone E00626 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium aluminum silicate E00462 3084116 Adsorbent; Binding agent; Disintegrant; Suspending agent; Viscosity-controlling agent
Magnesium carbonate E00205 11029 Adsorbent; Diluent
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium chloride E00077 5234 Diluent; Tonicity agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Triethyl citrate E00128 6506 Plasticizing agent; Solvent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
⏷ Show the Full List of 38 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Lamotrigine 250 mg tablet 250 mg 24 HR Extended Release Oral Tablet Oral
Lamotrigine 100 mg tablet 100 mg Disintegrating Oral Tablet Oral
Lamotrigine 200 mg tablet 200 mg Disintegrating Oral Tablet Oral
Lamotrigine 25 mg tablet 25 mg Disintegrating Oral Tablet Oral
Lamotrigine 50 mg tablet 50 mg Disintegrating Oral Tablet Oral
Lamotrigine 100 mg tablet 100 mg 24 HR Extended Release Oral Tablet Oral
Lamotrigine 300 mg tablet 300 mg 24 HR Extended Release Oral Tablet Oral
Lamotrigine 50 mg tablet 50 mg 24 HR Extended Release Oral Tablet Oral
Lamotrigine 25 mg tablet 25 mg Chewable Tablet Oral
Lamotrigine 5 mg tablet 5 mg Chewable Tablet Oral
Lamotrigine 200 mg tablet 200 mg 24 HR Extended Release Oral Tablet Oral
Lamotrigine 25 mg tablet 25 mg 24 HR Extended Release Oral Tablet Oral
Lamotrigine 100 mg tablet 100 mg Oral Tablet Oral
Lamotrigine 200 mg tablet 200 mg Oral Tablet Oral
Lamotrigine 2 mg tablet 2 mg Chewable Tablet Oral
Lamotrigine 150 mg tablet 150 mg Oral Tablet Oral
Lamotrigine 25 mg tablet 25 mg Oral Tablet Oral
Lamotrigine 250 mg tablet 250 mg Oral Tablet Oral
Lamotrigine 50 mg tablet 50 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2622).
2 Use of second-generation antiepileptic drugs in the pediatric population. Paediatr Drugs. 2008;10(4):217-54.
3 BDDCS applied to over 900 drugs
4 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5 Lamictal FDA Label
6 Gomes RL, Meredith W, Snape CE, Sephton MA: Analysis of conjugated steroid androgens: deconjugation, derivatisation and associated issues. J Pharm Biomed Anal. 2009 Jul 12;49(5):1133-40. doi: 10.1016/j.jpba.2009.01.027. Epub 2009 Jan 31.
7 Lamotrigine clinical pharmacokinetics. Clin Pharmacokinet. 1993 Dec;25(6):433-43. doi: 10.2165/00003088-199325060-00003.
8 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9 The effects of lamotrigine on the acquisition and expression of morphine-induced place preference in mice. Pak J Biol Sci. 2009 Jan 1;12(1):33-9.
10 Lamotrigine is a substrate for OCT1 in brain endothelial cells. Biochem Pharmacol. 2012 Mar 15;83(6):805-14.
11 Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology. 2008 Dec;55(8):1364-75.
12 Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
13 Variation in glucuronidation of lamotrigine in human liver microsomes. Xenobiotica. 2009 May;39(5):355-63.
14 Studies on induction of lamotrigine metabolism in transgenic UGT1 mice. Xenobiotica. 2009 Nov;39(11):826-35.
15 Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
16 Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
17 Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
18 UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
19 Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
20 Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
21 Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
22 Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
23 Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
24 Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005 Jul;33(7):1027-35.
25 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
26 UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone. Mol Diagn Ther. 2013 Aug;17(4):233-7.
27 Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011 May;21(5):280-8.
28 Pitavastatin: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2017 Apr;17(2):157-168.
29 Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9.
30 Drug interactions between the immunosuppressant tacrolimus and the cholesterol absorption inhibitor ezetimibe in healthy volunteers. Clin Pharmacol Ther. 2011 Apr;89(4):524-8.
31 Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
32 FDA label of Lorlatinib. The 2020 official website of the U.S. Food and Drug Administration.
33 Human biotransformation of the nonnucleoside reverse transcriptase inhibitor rilpivirine and a cross-species metabolism comparison. Antimicrob Agents Chemother. 2013 Oct;57(10):5067-79.
34 Identification of human UDP-glucuronosyltransferases catalyzing hepatic 1alpha,25-dihydroxyvitamin D3 conjugation. Biochem Pharmacol. 2008 Mar 1;75(5):1240-50.
35 Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection. Antivir Chem Chemother. 2008;19(3):107-13.
36 Identification of aspartic acid and histidine residues mediating the reaction mechanism and the substrate specificity of the human UDP-glucuronosyltransferases 1A. J Biol Chem. 2007 Dec 14;282(50):36514-24.
37 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
38 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
39 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
40 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
41 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
42 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
43 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
44 Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
45 Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
46 Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
47 Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
48 Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
49 Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
50 Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
51 Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
52 Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
53 Mechanisms of analgesia of intravenous lidocaine. Rev Bras Anestesiol. 2008 May-Jun;58(3):280-6.
54 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
55 Secondary injury mechanisms of spinal cord trauma: a novel therapeutic approach for the management of secondary pathophysiology with the sodium channel blocker riluzole. Prog Brain Res. 2002;137:177-90.
56 Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther. 2005 Dec;315(3):1237-46.
57 New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22.
58 Debate: Does genetic information in humans help us treat patients PRO--genetic information in humans helps us treat patients. CON--genetic information does not help at all. Epilepsia. 2008 Dec;49 Suppl 9:13-24.
59 Emerging drugs for spinal cord injury. Expert Opin Emerg Drugs. 2008 Mar;13(1):63-80.
60 Voltage-gated sodium channel blockers for the treatment of chronic pain. Curr Top Med Chem. 2009;9(4):362-76.
61 Belcastro V, Costa C, Striano P "Levetiracetam-associated hyponatremia." Seizure 17 (2008): 389-90. [PMID: 18584781]
62 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
63 Cerner Multum, Inc. "Australian Product Information.".
64 American Epilepsy Society "FDA Safety Warning on the Cardiac Effects of Lamotrigine: An Advisory from the Ad Hoc ILAE/AES Task Force. [PMID: 33641454]
65 Ebert U, Thong NQ, Oertel R, Kirch W "Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects." Eur J Clin Pharmacol 56 (2000): 299-304. [PMID: 10954343]
66 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
67 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
68 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
69 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
70 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
71 Bigham S, McGuigan C, MacDonald BK "Reduced absorption of lipophilic anti-epileptic medications when used concomitantly with the anti-obesity drug orlistat." Epilepsia 47 (2006): 2207. [PMID: 17201727]
72 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
73 Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
74 Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
75 Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.